Jump Financial’s Arcus Biosciences RCUS Stock Holding History

Jump Financial’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.53M	Sell	82,036 -53,764	-40%	-$1.33M	0.02%	795
2026 Q1	$2.93M	Buy	+135,800	New	+$2.93M	0.04%	516
2025 Q1	–	Sell	-17,244	Closed	-$257K	–	1947
2024 Q4	$257K	Buy	+17,244	New	+$282K	0.01%	1384
2024 Q2	–	Sell	-32,190	Closed	-$608K	–	2176
2024 Q1	$608K	Buy	+32,190	New	+$557K	0.02%	1066
2023 Q3	–	Sell	-63,921	Closed	-$1.3M	–	2175
2023 Q2	$1.3M	Buy	+63,921	New	+$1.22M	0.05%	554
2022 Q1	–	Sell	-9,783	Closed	-$396K	–	1847
2021 Q4	$396K	Buy	+9,783	New	+$379K	0.02%	763
2021 Q1	–	Sell	-17,359	Closed	-$451K	–	1223
2020 Q4	$451K	Sell	17,359 -2,776	-14%	-$67.2K	0.08%	413
2020 Q3	$345K	Buy	+20,135	New	+$450K	0.07%	449

Other funds holding RCUS

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Jump Financial's RCUS Position: Q2 2026 in Review

Jump Financial reduced its Arcus Biosciences (RCUS) stake by 40% in Q2 2026, selling an estimated $1.33M and leaving 82,036 shares worth $2.53M. The position accounts for 0.02% of the portfolio, ranked #795.

Jump Financial first reported a position in RCUS in Q3 2020 and has held it in 8 quarters since. The position peaked at $2.93M in Q1 2026. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

Jump Financial held 82,036 shares of Arcus Biosciences worth $2.53M as of Q2 2026.
Jump Financial sold 53,764 Arcus Biosciences shares in Q2 2026, an estimated $1.33M.
Arcus Biosciences made up 0.02% of Jump Financial's portfolio in Q2 2026, its #795 holding.
Jump Financial first reported a position in Arcus Biosciences in Q3 2020 and has held it in 8 quarters since.
Jump Financial's Arcus Biosciences position peaked at $2.93M in Q1 2026.
231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.